Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has covered health care and the biopharma industry for over 12 years. He started out covering retail pharmacy for Drug Store News and shifted to writing for the pharma audience at BioPharm Insight, where highlights of his coverage included breaking stories about the early growing pains of CAR-T cell therapy development. Most recently he covered the biopharma beat at MedCity News. His professional interests include cell and gene therapies, hematology-oncology and the intersection of biopharma with artificial intelligence and machine learning. A native of Seattle, he holds a bachelor degree in journalism from Ball State University and also lived in China for three years. He is currently based in Brooklyn. Outside of work, Alaric’s interests include reading, coin collecting, travel and languages.

Latest From Alaric DeArment

Bluebird Spins Off Oncology Business As Cell, Gene Therapy Segments Grow Apart

Nick Leschly will become CEO of oncology-focused spinoff, while Andrew Obenshain will help gene therapy-focused bluebird

Commercial Business Strategies

Alnylam's Phase III Results For Vutrisiran Are 'Foundation' For Amyloidosis Expansion

The results are in for hATTR amyloidosis with polyneuropathy, while results for hereditary and wild-type ATTR with cardiomyopathy are expected later this year.

Research & Development Research and Development Strategies

Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer

The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.

BioPharmaceutical Cancer

BioXcel's BXCL501 Data In Dementia Patients Reinforce Its Efficacy In Agitation

Execs said data from the institutional setting could be a bridge to other settings, while the duration of response indicates a real-world benefit that could aid adoption.

BioPharmaceutical Research & Development

Moderna Increases Minimum Supply Of Coronavirus Vaccine Doses For 2021

The company’s announcement that it would supply at least 600 million doses of mRNA-1273 came as US vaccination rates have fallen far short of expectations.

BioPharmaceutical Infectious Diseases

How COVID-19 Defined 2020 For Biopharma

Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.

Coronavirus COVID-19 Infectious Diseases
See All
UsernamePublicRestriction

Register